CHMP recommends approval of Lilly and Incyte's Olumiant (baricitinib) as the first and only centrally authorised treatment for adults with severe alopecia areata

Eli Lilly

20 May 2022 - Eli Lilly and Incyte announced today that the EMA's CHMP has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata.

This opinion marks the first step toward European regulatory approval of Olumiant for patients with severe alopecia areata, and it is now referred to the European Commission for final action.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe